Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:FLGT
- CUSIP: N/A
- Web: www.fulgentgenetics.com
Capitalization:- Market Cap: $117.12 million
- Outstanding Shares: 17,692,000
Average Prices:- 50 Day Moving Avg: $6.14
- 200 Day Moving Avg: $9.51
- 52 Week Range: $4.49 - $13.90
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 15.76
- P/E Growth: 0.71
Sales & Book Value:- Annual Revenue: $20.14 million
- Price / Sales: 5.82
- Book Value: $3.13 per share
- Price / Book: 2.12
Profitability:- EBIDTA: $3.13 million
- Return on Equity: 0.21%
- Return on Assets: 0.11%
Debt:- Current Ratio: 10.11%
- Quick Ratio: 10.11%
Misc:- Average Volume: 49,257 shs.
- Short Ratio: 2.13
Frequently Asked Questions for Fulgent Genetic (NASDAQ:FLGT)
What is Fulgent Genetic's stock symbol?
Fulgent Genetic trades on the NASDAQ under the ticker symbol "FLGT."
How were Fulgent Genetic's earnings last quarter?
Fulgent Genetic (NASDAQ:FLGT) announced its quarterly earnings results on Monday, May, 8th. The company reported $0.02 EPS for the quarter, missing the Zacks' consensus estimate of $0.03 by $0.01. The company had revenue of $5.31 million for the quarter, compared to analysts' expectations of $5.85 million. View Fulgent Genetic's Earnings History.
Where is Fulgent Genetic's stock going? Where will Fulgent Genetic's stock price be in 2017?
3 analysts have issued 12 month target prices for Fulgent Genetic's stock. Their forecasts range from $13.00 to $15.00. On average, they anticipate Fulgent Genetic's share price to reach $13.67 in the next year. View Analyst Ratings for Fulgent Genetic.
Who are some of Fulgent Genetic's key competitors?
Some companies that are related to Fulgent Genetic include Cytosorbents Corporation (CTSO), Alliance HealthCare Services (AIQ), Viveve Medical (VIVE), IRIDEX Corporation (IRIX), Cogentix Medical (CGNT), Edap Tms S.A. (EDAP), Neovasc Inc (US) (NVCN), Harvard Bioscience (HBIO), Digirad Corporation (DRAD), Biolase (BIOL), Electromed (ELMD), Presbia PLC (LENS), EnteroMedics (ETRM), Xtant Medical Holdings (XTNT), Advanced Oncotherapy PLC (AVO), Sphere Medical Holding PLC (SPHR), PhotoMedex (PHMD) and Dextera Surgical (DXTR).
Who are Fulgent Genetic's key executives?
Fulgent Genetic's management team includes the folowing people:
- Ming Hsieh, Chairman of the Board, President, Chief Executive Officer
- Paul Kim, Chief Financial Officer
- Hanlin Gao M.D., Ph.D., Lab Director and Chief Scientific Officer
- John Bolger, Director
- James J. Mulay, Director
- Yun Yen M.D., Ph.D., Director
When did Fulgent Genetic IPO?
(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.
How do I buy Fulgent Genetic stock?
Shares of Fulgent Genetic can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fulgent Genetic's stock price today?
One share of Fulgent Genetic stock can currently be purchased for approximately $6.62.
MarketBeat Community Rating for Fulgent Genetic (NASDAQ FLGT)MarketBeat's community ratings are surveys of what our community members think about Fulgent Genetic and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Fulgent Genetic (NASDAQ:FLGT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $13.67 (106.45% upside) |
Analysts' Ratings History for Fulgent Genetic (NASDAQ:FLGT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 11/4/2016 | Credit Suisse Group | Reiterated Rating | Buy | $13.00 | N/A |  |
| 10/24/2016 | BTIG Research | Initiated Coverage | Buy | $15.00 | N/A | |
| 10/24/2016 | Piper Jaffray Companies | Initiated Coverage | Overweight | $13.00 | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for Fulgent Genetic (NASDAQ:FLGT)Earnings History by Quarter for Fulgent Genetic (NASDAQ FLGT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2017 | Q1 2017 | $0.03 | $0.02 | $5.85 million | $5.31 million | View | Listen | |
| 2/27/2017 | Q416 | $0.04 | $0.05 | $5.99 million | $5.85 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Fulgent Genetic (NASDAQ:FLGT)Current Year EPS Consensus Estimate: $0.16 EPS
Next Year EPS Consensus Estimate: $0.42 EPS
Dividend History for Fulgent Genetic (NASDAQ:FLGT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Fulgent Genetic (NASDAQ:FLGT)Institutional Ownership Percentage: 19.78%
Insider Trades by Quarter for Fulgent Genetic (NASDAQ:FLGT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/15/2017 | Ming Hsieh | Insider | Buy | 20,000 | $5.26 | $105,200.00 | |
| 6/13/2017 | Ming Hsieh | Insider | Buy | 30,000 | $4.98 | $149,400.00 | |
| 9/30/2016 | Ming Hsieh | Insider | Buy | 1,000,000 | $9.00 | $9,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Fulgent Genetic (NASDAQ:FLGT)
Latest Headlines for Fulgent Genetic (NASDAQ:FLGT)
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Fulgent Genetic (FLGT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - July 24 at 9:57 AM |
| Fulgent Genetic (NASDAQ:FLGT) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 10 at 7:14 PM |
 | ETFs with exposure to Fulgent Genetics, Inc. : June 26, 2017
finance.yahoo.com - June 26 at 6:34 PM |
| Cytosorbents Corporation (CTSO) and FULGENT GENETIC (FLGT) Head-To-Head Analysis
www.americanbankingnews.com - June 25 at 10:08 AM |
| ETFs with exposure to Fulgent Genetics, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 5:53 PM |
| Fulgent Genetic (FLGT) Insider Acquires $105,200.00 in Stock
www.americanbankingnews.com - June 15 at 10:26 PM |
| Brokerages Set $10.75 Price Target for Fulgent Genetic (FLGT)
www.americanbankingnews.com - June 15 at 4:34 PM |
| Fulgent Genetics, Inc. :FLGT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 6:28 PM |
| Fulgent Genetic (FLGT) Insider Purchases $149,400.00 in Stock
www.americanbankingnews.com - June 13 at 10:32 PM |
| Zacks: Fulgent Genetics Inc (FLGT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 30 at 10:47 PM |
| Why FULGENT GENETICS (FLGT) Could Be Positioned for a Slump
finance.yahoo.com - May 16 at 11:44 AM |
| Fulgent Genetics Inc (FLGT) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - May 12 at 10:06 PM |
| Edited Transcript of FLGT earnings conference call or presentation 8-May-17 9:00pm GMT
finance.yahoo.com - May 9 at 5:04 PM |
| Fulgent Genetics Inc (FLGT) Posts Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 9 at 4:32 PM |
| Investor Network: Fulgent Genetics, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 5:02 PM |
| Fulgent Genetics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 5:02 PM |
| Zacks: Analysts Set $13.25 Price Target for Fulgent Genetics Inc (FLGT)
www.americanbankingnews.com - May 6 at 12:34 AM |
| Fulgent Genetics Inc (FLGT) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 27 at 6:34 PM |
| Zacks: Fulgent Genetics Inc (FLGT) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 20 at 8:28 PM |
| Fulgent Genetics Inc (FLGT) Short Interest Update
www.americanbankingnews.com - April 20 at 7:21 PM |
| ETFs with exposure to Fulgent Genetics, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 5:07 PM |
 | Fulgent Genetics: The Next Big Healthcare Stock?
seekingalpha.com - April 8 at 9:46 AM |
| ETFs with exposure to Fulgent Genetics, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 5:08 PM |
| Fulgent Genetics Inc (FLGT) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 29 at 8:24 PM |
| Fulgent Genetics Inc (FLGT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 22 at 7:16 PM |
| Fulgent Genetics Inc's Lock-Up Period To End on March 28th (NASDAQ:FLGT)
www.americanbankingnews.com - March 21 at 7:07 AM |
| Short Fulgent Genetics; Major Stock Holders Could Sell At Lock-Up Expiration
seekingalpha.com - March 17 at 5:31 PM |
| FULGENT GENETICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 17 at 5:31 PM |
| Fulgent Genetics Inc (FLGT) Lifted to “Hold” at Zacks Investment Research
www.americanbankingnews.com - March 16 at 6:50 PM |
| Q4 2016 Fulgent Genetics Inc Earnings Release - After Market Close
us.rd.yahoo.com - March 1 at 9:57 PM |
| Fulgent Genetics to Participate in 2017 BTIG Medical Technology, Life Science and Diagnostic Tools Conference
finance.yahoo.com - February 27 at 7:15 PM |
 | Fulgent Genetics Reports Fourth Quarter and Full Year 2016 Financial Results
globenewswire.com - February 27 at 7:15 PM |
| Fulgent Genetics beats by $0.02, misses on revenue
seekingalpha.com - February 27 at 7:15 PM |
| Fulgent Genetics Inc Earnings Call scheduled for 5:00 pm ET today
biz.yahoo.com - February 27 at 7:15 PM |
| Fulgent Genetics to Announce Fourth Quarter and Full Year 2016 Financial Results on February 27, 2017
finance.yahoo.com - February 16 at 5:10 PM |
| Fulgent Genetics, Inc. to Participate in Fireside Chat at the 28th Annual Piper Jaffray Healthcare Conference on November 29, 2016
finance.yahoo.com - November 15 at 8:21 AM |
| FULGENT GENETICS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 14 at 5:18 PM |
| Edited Transcript of FLGT earnings conference call or presentation 3-Nov-16 9:00pm GMT
finance.yahoo.com - November 7 at 5:04 PM |
| Q3 2016 Fulgent Genetics Inc Earnings Release - After Market Close
biz.yahoo.com - November 4 at 7:39 AM |
| FULGENT GENETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
biz.yahoo.com - November 3 at 4:48 PM |
 | Fulgent Genetics, Inc. to Announce Third Quarter 2016 Financial
www.nasdaq.com - October 28 at 4:53 PM |
| Fulgent Genetics, Inc. to Announce Third Quarter 2016 Financial Results on November 3, 2016
finance.yahoo.com - October 26 at 8:12 AM |
| Fulgent Genetics, Inc. to Present at the 25th Annual Credit Suisse Healthcare Conference on November 7, 2016
finance.yahoo.com - October 25 at 9:56 AM |
| Fulgent Is 'Making A Splash' In The Genetics Pool
finance.yahoo.com - October 24 at 4:52 PM |
| Fulgent Genetics 'Blazing a Different Path'; Piper Initiates At Overweight
finance.yahoo.com - October 24 at 4:52 PM |
 | BTIG Initiates Fulgent Genetics At Buy; Co. Is A 'Rare Find' In Genetics
www.benzinga.com - October 24 at 10:17 AM |
 | Fulgent Genetics Inc (FLGT.OQ)
www.reuters.com - October 17 at 5:00 PM |
| Fulgent Genetics, Inc. Announces Closing of Initial Public Offering
finance.yahoo.com - October 5 at 3:33 PM |
Fulgent Genetic (FLGT) Chart for Tuesday, July, 25, 2017
